• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Relmada Therapeutics Inc. (Amendment)

    2/14/23 4:13:42 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RLMD alert in real time by email
    SC 13G/A 1 pt7213gaa.htm SCHEDULE 13G/A, AMENDMENT #1
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.

    Securities and Exchange Commission, Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

    (Name of Issuer)

    Relmada Therapeutics, Inc.

    (Title of Class of Securities)

    Common Stock, par value $0.001 per share

    (CUSIP Number)

    75955J402

    (Date of Event Which Requires Filing of this Statement)

    December 31, 2022

    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:

    [  ] Rule 13d-1(b)

    [ x ] Rule 13d-1(c)

    [  ] Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.


    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).


    CUSIP No. 75955J402
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              0
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       0
     
    (9) Aggregate amount beneficially owned by each reporting person
                                                          0
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0%
     
    (12) Type of reporting person (see instructions) PN
     



    CUSIP No. 75955J402
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              0
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       0
     
    (9) Aggregate amount beneficially owned by each reporting person
    0
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0%
     
    (12) Type of reporting person (see instructions) CO
     


    CUSIP No. 75955J402
    (1) Names of reporting persons    Cubist Systematic Strategies, LLC
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              40,690
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       40,690
     
    (9) Aggregate amount beneficially owned by each reporting person
    40,690
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0.1%
     
    (12) Type of reporting person (see instructions) OO
     


    CUSIP No. 75955J402
    (1) Names of reporting persons    Point72 Middle East FZE
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United Arab Emirates
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              15,517
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       15,517
     
    (9) Aggregate amount beneficially owned by each reporting person
    15,517
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0.1%
     
    (12) Type of reporting person (see instructions) OO
     


    CUSIP No. 75955J402
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              56,207
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       56,207
     
    (9) Aggregate amount beneficially owned by each reporting person
    56,207
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0.2%
     
    (12) Type of reporting person (see instructions) IN
     



    Item 1(a) Name of issuer:

    Relmada Therapeutics, Inc.
    Item 1(b) Address of issuer's principal executive offices:

    2222 Ponce de Leon, Floor 3, Coral Gables, FL 33134

    2(a) Name of person filing:

    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”)
    with respect to shares of common stock, par value $0.001 per share (“Shares”), of the Issuer held
    by an investment fund it manages; (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors
    Inc.”) with respect to Shares held by an investment fund managed by Point72 Asset
    Management; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic Strategies”) with
    respect to Shares held by an investment fund it manages; (iv) Point72 Middle East FZE
    (“Point72 Middle East”) with respect to Shares held by an investment fund it manages; and (v)
    Steven A. Cohen (“Mr. Cohen”) with respect to Shares beneficially owned by Point72 Asset
    Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Point72 Middle
    East.

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, Point72
    Middle East, and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed
    with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule
    13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

    2(b) Address or principal business office or, if none, residence:

    The address of the principal business office of (i) Point72 Asset Management, Point72 Capital
    Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902; (ii) Cubist
    Systematic Strategies is 55 Hudson Yards, New York, NY 10001; and (iii) Point72 Middle East
    is EO3, 04, Sheikh Rashid Tower, Dubai World Trade Centre, Dubai, United Arab Emirates.

    2(c) Citizenship:

    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a
    Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company.
    Point72 Middle East is a limited liability free zone establishment. Mr. Cohen is a United States
    citizen.

    2(d) Title of class of securities:

    Common Stock, par value $0.001 per share


    2(e) CUSIP Number:

    75955J402

    Item 3.

    Not applicable


    Item 4. Ownership

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for
    each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
    Such information is as of the close of business on December 31, 2022.

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, Point72
    Middle East, and Mr. Cohen own directly no Shares. Pursuant to an investment management
    agreement, Point72 Asset Management maintains investment and voting power with respect to
    the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general
    partner of Point72 Asset Management. Pursuant to an investment management agreement, Cubist
    Systematic Strategies maintains investment and voting power with respect to the securities held
    by an investment fund it manages. Pursuant to an investment management agreement, Point72
    Middle East maintains investment and voting power with respect to the securities held by an
    investment fund it manages. Mr. Cohen controls each of Point72 Asset Management, Point72
    Capital Advisors Inc., Cubist Systematic Strategies, and Point72 Middle East.   The filing of this
    statement should not be construed as an admission that any of the foregoing persons or any
    reporting person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares
    reported herein.

    Item 5.  Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [X].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    See Item 2(a)

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.

    Not applicable

    Item 8. Identification and Classification of Members of the Group

    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to
    above were not acquired and are not held for the purpose of or with the effect of changing or
    influencing the control of the issuer of the securities and were not acquired and are not held in
    connection with or as a participant in any transaction having that purpose or effect.

    Signature.  After reasonable inquiry and to the best of my knowledge and belief, I
    certify that the information set forth in this statement is true, complete and correct.


    Dated: February 14, 2023


    POINT72 ASSET MANAGEMENT, L.P.

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    POINT72 CAPITAL ADVISORS, INC.

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    CUBIST SYSTEMATIC STRATEGIES, LLC

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    POINT72 MIDDLE EAST FZE

    By: /s/ Rafael Lopez Espinosa
    Name: Rafael Lopez Espinosa
    Title: Authorized Person


    STEVEN A. COHEN

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person
    Get the next $RLMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RLMD

    DatePrice TargetRatingAnalyst
    12/5/2024$23.00 → $1.00Outperform → Neutral
    Mizuho
    9/17/2024$3.50 → $13.00Hold → Buy
    Jefferies
    6/5/2024$3.00 → $2.00Neutral → Sell
    Goldman
    10/14/2022$81.00 → $8.00Buy → Neutral
    Goldman
    10/14/2022$90.00 → $10.00Buy → Hold
    Truist
    10/14/2022Buy → Neutral
    Guggenheim
    10/13/2022$64.00 → $7.00Outperform → Perform
    Oppenheimer
    12/20/2021$50.00 → $42.00Outperform
    SVB Leerink
    More analyst ratings

    $RLMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 study for NDV-01 continues with updates at 6, 9 and 12 month data follow-up over the course of 2025. Plans to start Phase III registration trial in H1 2026 Expecting to initiate a Phase 2 study for sepranolone in Prader-Willi syndrome in H1 2026 (US prevalence 20,000 patients) Conference Call and Webcast Today at 4:30 PM ET CORAL GABLES, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advanci

      5/12/25 4:01:00 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", or "the Company")), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress. Conference Call and Webcast Information: Date: Monday, May 12, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Conference: 13753596Webcast Access: Click Here A replay of the webcast will be available in the

      5/8/25 7:30:00 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

      90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept for sustained-release "GEM/DOCE" formulation* NDV-01 showed promising clinical activity in BCG-naïve and BCG-unresponsive patients, with favorable overall tolerability Data to be reviewed at Investor Event on April 28, 2025 at 4:30 PM ET CORAL GABLES, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a clinical-stage biotechnology company, today announced that positive initial data from the Phase 2 study of NDV-01 showed that 90% of patients achieved high-grade disease-free status at any time point

      4/28/25 1:38:43 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Relmada Therapeutics downgraded by Mizuho with a new price target

      Mizuho downgraded Relmada Therapeutics from Outperform to Neutral and set a new price target of $1.00 from $23.00 previously

      12/5/24 8:17:30 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics upgraded by Jefferies with a new price target

      Jefferies upgraded Relmada Therapeutics from Hold to Buy and set a new price target of $13.00 from $3.50 previously

      9/17/24 7:49:37 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics downgraded by Goldman with a new price target

      Goldman downgraded Relmada Therapeutics from Neutral to Sell and set a new price target of $2.00 from $3.00 previously

      6/5/24 7:16:28 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Kelly Paul Edward bought $86,060 worth of shares (200,000 units at $0.43), increasing direct ownership by 94% to 412,295 units (SEC Form 4)

      4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

      5/20/25 6:03:44 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Shenouda Maged bought $97,208 worth of shares (200,000 units at $0.49), increasing direct ownership by 226% to 288,335 units (SEC Form 4)

      4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

      5/20/25 6:03:12 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CA and CO Ence Chuck bought $103,330 worth of shares (228,961 units at $0.45), increasing direct ownership by 588% to 267,931 units (SEC Form 4)

      4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

      5/20/25 6:02:33 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLMD
    Financials

    Live finance-specific insights

    See more
    • Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 study for NDV-01 continues with updates at 6, 9 and 12 month data follow-up over the course of 2025. Plans to start Phase III registration trial in H1 2026 Expecting to initiate a Phase 2 study for sepranolone in Prader-Willi syndrome in H1 2026 (US prevalence 20,000 patients) Conference Call and Webcast Today at 4:30 PM ET CORAL GABLES, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advanci

      5/12/25 4:01:00 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", or "the Company")), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress. Conference Call and Webcast Information: Date: Monday, May 12, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Conference: 13753596Webcast Access: Click Here A replay of the webcast will be available in the

      5/8/25 7:30:00 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

      Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), to be presented at AUA 2025 in April Advancing novel neurosteroid, sepranolone, towards Phase 2b study in Tourette syndrome with plans for evaluation in other compulsion-related disorders, including Prader-Willi Syndrome Cash balance of $44.8 million as of December 31 2024 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a clinical-stage biotechnology company, today provided a corporate update and announced preliminary and unaudited financial re

      3/27/25 4:05:00 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Kelly Paul Edward bought $86,060 worth of shares (200,000 units at $0.43), increasing direct ownership by 94% to 412,295 units (SEC Form 4)

      4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

      5/20/25 6:03:44 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Shenouda Maged bought $97,208 worth of shares (200,000 units at $0.49), increasing direct ownership by 226% to 288,335 units (SEC Form 4)

      4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

      5/20/25 6:03:12 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CA and CO Ence Chuck bought $103,330 worth of shares (228,961 units at $0.45), increasing direct ownership by 588% to 267,931 units (SEC Form 4)

      4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

      5/20/25 6:02:33 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Relmada Therapeutics Inc.

      SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

      11/14/24 9:41:31 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Relmada Therapeutics Inc. (Amendment)

      SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

      3/6/24 4:15:42 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Relmada Therapeutics Inc. (Amendment)

      SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

      2/14/24 8:53:47 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLMD
    SEC Filings

    See more
    • SEC Form 10-Q filed by Relmada Therapeutics Inc.

      10-Q - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)

      5/12/25 4:06:07 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)

      5/12/25 4:05:54 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Relmada Therapeutics Inc.

      424B5 - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)

      4/28/25 1:46:21 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors

      CORAL GABLES, Fla., Jan. 12, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Fabiana Fedeli, Chief Investment Officer Equities, Multi Asset and Sustainability, at M&G Investments, one of the United Kingdom's largest and longest established investment houses, as an independent director to the Company's Board of Directors. Ms. Fedeli has extensive knowledge of international capital markets, sustainability, governance and corporate strategy

      1/12/23 8:00:00 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer

      CORAL GABLES, Fla., Jan. 9, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Cedric O'Gorman MD as the Company's Chief Medical Officer. Dr. O'Gorman will lead medical, clinical and regulatory functions in support of the Company's late-stage REL-1017 development program.  Dr. O'Gorman brings to Relmada more than two decades of life sciences experience in clinical development, medical affairs and medical strategy, with significant expertise

      1/9/23 8:00:00 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial

      Company Continues Commercial Preparations in Advance of Phase III Clinical Trial Readouts for REL-1017 in Major Depressive Disorder Expected in 2022 CORAL GABLES, Fla., July 21, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of John Hixon to a newly created position as Head of Commercial. Mr. Hixon has over 36 years of commercial planning and marketing experience within the biopharmaceutical industry. "My due diligence performed before joi

      7/21/22 8:30:00 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care